Late Effects after Transplantation for Pediatric Severe Aplastic Anemia. Jean E. Sanders, M.D.

Size: px
Start display at page:

Download "Late Effects after Transplantation for Pediatric Severe Aplastic Anemia. Jean E. Sanders, M.D."

Transcription

1 Late Effects after Transplantation for Pediatric Severe Aplastic Anemia Jean E. Sanders, M.D.

2 Patient Characteristics Acquired Fanconi Number Gender F:M 63:74 9:6 Etiology: Idiopathic Hepatitis PNH Insecticide Age at Diagnosis Median (range) 10.7 ( ) 6.3 ( ) Years Dx to Tx Median (range) 0.1 ( ) 2.0 ( ) Age at Transplant Median (range) 11.1 ( ) 9.0 ( ) Years Follow-up Median (range) 21.8 (1 38.1) 20 (2-30)

3 Transplant Characteristics First Transplant Regimen S-TBI Fx TBI 12 Gy Fx TBI 2-6 Gy CY + ATG PAPAPACY None Acquired Fanconi 4 11 Second/Third Regimens 15/4 Donor Related Unrelated Syngeneic Acute GVHD 41 (30%) 9 (60%) Chronic GVHD 36 5

4 Survival of Acquired and Fanconi AA Children

5 Late Causes of Death 1-5 years Suicide Chronic GVHD Measles Pneumonia Hemolytic Anemia 5-32 years Pulmonary Failure Malignancy Suicide HIV Hepatitis C Liver Failure Chronic GVHD Acquired Fanconi 2 1 1

6 Mortality Risk Factors Multivariate Analysis Diagnosis Acquired AA Fanconi AA HR (95% CI) (1.4-14) P-value 0.03 Chronic GVHD No Yes ( ) (1.4-10)

7 Survival among AA children with and without chronic GVHD

8 Risk Factors for Chronic GVHD Multivariate Analysis Buffy Coat No Yes Donor Match related Mismatch related Unrelated HR (95% CI) ( ) (2.6-19) 1.98 ( ) P-value

9 Unrelated Donor Transplants N = acquired 15 survive 1-24 years 3 Fanconi 2 survive 5 and 10 years Among the 16 acquired 11 (69%) had chronic GVHD Among the 3 Fanconi 1 died of chronic GVHD

10 Chimerism Not determined for 22 patients transplanted prior to 1976 Among the 130 after that time: 2 were twins 2 (1.5%) had autologous recovery 1 had stable mixed donor/host chimerism 103 had 100% donor chimerism

11 Gonadal Function Acquired AA -- Females Pre-Pubertal Post-Pubertal No. patients Still Pre-pubertal Evaluable Normal develop 30 Abnormal gonad f n -- 1 Early menopause -- 1

12 Gonadal Function Acquired AA -- Males Pre-Pubertal Post-Pubertal Number patients Still pre-pubertal Evaluable Normal develop Abn l gonadotropin 8 9 Low testosterone 0 1

13 Pregnancies after Transplant Regimen CY TBI Gender Female Male* Female Pre-birth Evaluable pregnancies Live Births 58 (82%) 47 (80%) Abortions Birth Defects

14 Growth of Acquired CY AA Children

15 Malignancy Fanconi Patients 2/15 (13%) Fanconi patients developed malignancy 9 and 12 years post-tx 1 developed adenocarcinoma of the colon and is surviving 1 developed metastatic squamous carcinoma which was cause of death

16 Malignancy Acquired AA patients 19/137 (13%) developed malignancy 1-31 years after transplant. 3 thyroid malignancy all survive 1 PNH developed MDS second tx 1 developed melanoma successful treated 7 developed squamous cell carcinoma which was cause of death for 1 3 developed breast cancer which was the cause of death for 1 1 patient died of metastatic cervical cancer 2 hepatocarcinoma assoc. with Hepatitis C 1 survives after liver transplant and 1 died

17 Hepatitis C disease 104 children transplanted prior to 1992 and 37 (35%) are known to be Hepatitis C positive. Among the 31 surviving with Hep C 1 required a liver transplant 12 were treated with ribavirin and/or interferon 5 no longer Hep C + 7 failed and 1 received a liver transplant 18 remain untreated

18 Quality of Life Formal QOL data available for 49 adult survivors of this pediatric AA transplant. SF-36 physical function and mental function studies among survivors and controls were not different from each other Also not different from controls was educational status, work or school status, financial situation or marital status. In contrast, insurance issues were significantly different for the transplant recipients for both health and life insurance.

19 Summary Marrow transplantation offers effective therapy for children with severe AA Majority who survive beyond one year after transplant grow up to become normal functioning adults. The children grow up and have normal children of their own. Overall, these former patients are doing very well.

20 INFANT ACUTE LEUEKMIA LATE EFFECTS Jean E. Sanders, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine

21 Infant ALL Population Number patients 25 Survival 23 Cause of Death 2 Relapse Time post HCT Age last follow-up 9.3 (1.8-21) yrs 10.5 ( ) yrs

22 Infant AML Population Number patients 9 Survival 6 Cause of Death Relapse 1 Secondary malignancy 1 Chronic GVHD 1 Time post HCT 18 (1-25) yrs Age last follow-up 20 ( ) yr

23 Infant Transplant Regimens Chemotherapy plus TBI 29 Busulfan + Cytoxan 5

24 Secondary Malignancies Number patients 3 Astrocytoma 1 fatal Thyroid (papillary) 1 alive Nerve Sheath tumor 1 alive

25 Cognitive Evaluations I Q Development School Performance

26 I Q Studies Number Studied 12 FSIQ 103 (66-119) PIQ 108 (63-120) VIQ 100 (75-126)

27 Development (subjective) Number patients 30 Normal 10 Speech delay 18 Motor delay 2 Catch-up speech/motor 20

28 School Performance Number evaluable 19 No problems noted 9 Special education 7 ADHD 3 Comments: A student Enjoys School Starting college Needs help Memory issue

29 Pulmonary Function Number Evaluable 20 Normal Function 17 Restrictive Lung Dz 3

30 Cardiac Studies Number patients 13 Normal Echocardiogram 9 Valve insufficiency 3

31 Dental Issues Number evaluated 15 Normal examination 2 Abnormal exam 13 Small jaw 5 Small palate 3 Missing teeth 5 Short roots 8

32 Endocrine Issues Growth Puberty Thyroid

33 Growth Growth Hormone evaluation 25 patients GH deficiency 17 pts (68%) GH therapy 10 pts Growth Z-scores -1.5 (-5.7 to +0.6)

34 BUCY 1 14 STANDARD DEVIATION CENTIMETERS / YEAR PRE YEARS POST TRANSPLANT YEARS OF AGE BOYS (N=18) GIRLS (N=18)

35 Puberty Evaluable patients 12 Normal development 7 Delayed development 3 Precocious puberty 3

36 Thyroid Function Number patients tested 18 Normal 2 CHT 11 Hypothyroid 2 Thyroiditis 1 Malignancy 2 - both Rx

37 Thyroid dysfunction by BMT age

38 Thyroid dysfunction by regimen

39 Conclusions Infants have the same problems after transplant as older transplanted children. Cognitive function is satisfactory even after TBI regimens. Development is delayed during the first year, but catch-up occurs. Dental issues must be followed. Endocrine problems may occur which need to be treated.

LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS

LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS Farid Boulad, Susan E Prockop, Praveen Anur, Danielle

More information

Endocrine Late Effects in Survivors of Pediatric SCT

Endocrine Late Effects in Survivors of Pediatric SCT Endocrine Late Effects in Survivors of Pediatric SCT Daphna Hutt Pediatric Hem-Onc & BMT Sheba Medical Center, Israel #EBMT2015 www.ebmt.org Stiller CA (2007). Childhood Cancer In Britain. Oxford University

More information

Late complications after hematopoietic stem cell transplant in adult patients

Late complications after hematopoietic stem cell transplant in adult patients Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity

More information

4100: Cellular Therapy Essential Data Follow-Up Form

4100: Cellular Therapy Essential Data Follow-Up Form 4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:

More information

Protecting Your Health After Transplant (Adults)

Protecting Your Health After Transplant (Adults) Protecting Your Health After Transplant (Adults) Navneet Majhail, MD, MS Medical Director, Health Services Research, National Marrow Donor Program Adjunct Associate Professor of Medicine, University of

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

Hematopoietic Cell Transplantation for Myelofibrosis. Outline

Hematopoietic Cell Transplantation for Myelofibrosis. Outline Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic

More information

Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life

Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life 1 Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center April 16, 2016 (40 min) Hematopoietic

More information

Long-Term Outcomes After Hematopoietic Cell Transplantation

Long-Term Outcomes After Hematopoietic Cell Transplantation Long-Term Outcomes After Hematopoietic Cell Transplantation Conflicts of Interest No relevant financial conflicts of interest Navneet Majhail, MD, MS Medical Director, NMDP Assistant Scientific Director,

More information

Survivorship After Stem Cell Transplantation and Long-term Followup

Survivorship After Stem Cell Transplantation and Long-term Followup Survivorship After Stem Cell Transplantation and Long-term Followup Navneet Majhail, MD, MS Director, Blood & Marrow Transplant Program, Cleveland Clinic Professor, Cleveland Clinic Lerner College of Medicine

More information

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal

More information

Outline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT

Outline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT Comorbidities before Allogeneic Hematopoietic Cell Transplantation (HCT) The HCT-specific Comorbidity Index (HCT-CI) Mohamed Sorror, M.D., M.Sc. FHCRC Seattle, WA Outline Pretransplant Essential data Why

More information

Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor

Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Saro Armenian, DO, MPH Associate Professor, Departments of Pediatrics and Population Sciences Director,

More information

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell

More information

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD. Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific

More information

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British

More information

Late effects, health status and quality of life after hemopoietic stem cell

Late effects, health status and quality of life after hemopoietic stem cell Late effects, health status and quality of life after hemopoietic stem cell transplantation (HSCT) THE 13th ESH-EBMT TRAINING COURSE ON BLOOD AND MARROW TRANSPLANTATION EBMT Slide template Barcelona 7

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014 Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of

More information

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation for Severe Aplastic Anemia Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center

More information

Coping with Pediatric Post-transplant Issues. K. Scott Baker, MD, MS Director, Pediatric Blood and Marrow Transplant and Survivorship Programs

Coping with Pediatric Post-transplant Issues. K. Scott Baker, MD, MS Director, Pediatric Blood and Marrow Transplant and Survivorship Programs Coping with Pediatric Post-transplant Issues K. Scott Baker, MD, MS Director, Pediatric Blood and Marrow Transplant and Survivorship Programs Risk Factors for Late Complications Pre-HCT exposures and comorbidities

More information

Review of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.

Review of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD. Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

Why? What? When? How? Dr C Fryer FRCPC) Surveillance

Why? What? When? How? Dr C Fryer FRCPC) Surveillance Why? What? When? How? Dr C Fryer FRCPC) Surveillance 1 Disclosure; Disclosure; None. I have no conflicts. I have no industry financial relationships. Background: Relapse is the single most likely late

More information

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility

More information

RIC in Allogeneic Stem Cell Transplantation

RIC in Allogeneic Stem Cell Transplantation RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants

More information

Late effects after HSCT

Late effects after HSCT Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

Late Complications. Navneet Majhail, MD, MS

Late Complications. Navneet Majhail, MD, MS Late Complications Navneet Majhail, MD, MS Medical Director, Health Services Research, NMDP Assistant Scientific Director, CIBMTR Adjunct Associate Professor of Medicine University of Minnesota Objectives

More information

Late Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT

Late Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT Objectives Late Complications Navneet Majhail, MD, MS Review late complications in hematopoietic cell transplant (HCT) recipients Review screening and prevention guidelines for HCT survivors Review upcoming

More information

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state

More information

Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor

Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor Saro Armenian, DO, MPH Associate Professor, Departments of Pediatrics and Population Sciences Director,

More information

Medical Late Effects of Childhood Cancer

Medical Late Effects of Childhood Cancer Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80

More information

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation

More information

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

SKIN CANCER AFTER HSCT

SKIN CANCER AFTER HSCT SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES

More information

Late effects and long-term survivorship after HSCT

Late effects and long-term survivorship after HSCT Late effects and long-term survivorship after HSCT André Tichelli What are late effects? Why is it of importance? How to proceed in daily routine? 59-year old male survivor 22 years after allogeneic HSCT

More information

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes

More information

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives

More information

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates

More information

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017 Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis

More information

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,

More information

Omori et al. SpringerPlus 2013, 2:424 a SpringerOpen Journal

Omori et al. SpringerPlus 2013, 2:424   a SpringerOpen Journal Omori et al. SpringerPlus 2013, 2:424 a SpringerOpen Journal RESEARCH Eleven secondary cancers after hematopoietic stem cell transplantation using a total body irradiation-based regimen in 370 consecutive

More information

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Rob Wynn RMCH & University of Manchester, UK. HCT in Children Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action

More information

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples 4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone

More information

Umbilical Cord Blood Transplantation

Umbilical Cord Blood Transplantation Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results

More information

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de

More information

Late effects and quality of life after haematological stem cell transplantation

Late effects and quality of life after haematological stem cell transplantation Late effects and quality of life after haematological stem cell transplantation Prof. dr hab. Ewa Gorczyńska Zofia Lutrowicz Department of Pediatric Hematology Oncology and Bone Marrow Transplantation,

More information

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases

More information

Hematopoietic Stem Cell Transplantation for Fanconi Anemia

Hematopoietic Stem Cell Transplantation for Fanconi Anemia Hematopoietic Stem Cell Transplantation for Fanconi Anemia John E. Wagner, M.D. Blood and Marrow Transplant Program University of Minnesota Cell Therapy for Pediatric Diseases NHLBI PACT Workshop 14 15

More information

Causes of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt

Causes of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt Causes of Death J. Douglas Rizzo, MD MS February, 2012 New11_1.ppt Overview Attribution of COD important for research purposes Frequently not correctly coded or completely reported Source of confusion

More information

Workshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan

Workshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors

More information

PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH

PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP Denise Rokitka, MD, MPH Objectives Describe incidence of childhood cancer and survival rates and causes of early mortality. Understand the late effects of cancer

More information

Mobilization & Pre-Transplant Conditioning Regimens

Mobilization & Pre-Transplant Conditioning Regimens Transplant Process & Pre-Transplant Conditioning Regimens (auto patients only) 30 days before BMT (allo donors) 5 days before BMT Conditioning (auto AND allo patients) Transplant A technique used to increase

More information

Disturbances of female reproductive system in survivors of childhood cancer

Disturbances of female reproductive system in survivors of childhood cancer Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the

More information

Targeted Radioimmunotherapy for Lymphoma

Targeted Radioimmunotherapy for Lymphoma Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,

More information

Disclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017

Disclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017 2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:

More information

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

Samples Available for Recipient and Donor

Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential

More information

Reduced-intensity Conditioning Transplantation

Reduced-intensity Conditioning Transplantation Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,

More information

PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey

PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties

More information

SAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team

SAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,

More information

ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES

ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES Corey Cutler, MD MPH FRCPC Associate Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute, Boston, MA HCT Outcomes - MDS 2001-2011

More information

Disclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

Disclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute. ALL in AYAs: Health Outcomes as a Criterion for Selecting Optimal Therapy David R. Freyer, DO, MS Director, Survivorship and Supportive Care Program, Children s Center for Cancer and Blood Diseases, Children

More information

PedsCases Podcast Scripts

PedsCases Podcast Scripts PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key

More information

Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center

Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center Trends in Pediatric Cancer Incidence Rates by Site, Ages Birth to 19 Years, 1975 to 2010.

More information

Pediatric Hematopoietic Stem Cell Transplantation. Meng Yao Lu/ Kai Hsin Lin Department of Pediatrics National Taiwan University Hospital

Pediatric Hematopoietic Stem Cell Transplantation. Meng Yao Lu/ Kai Hsin Lin Department of Pediatrics National Taiwan University Hospital Pediatric Hematopoietic Stem Cell Transplantation Meng Yao Lu/ Kai Hsin Lin Department of Pediatrics National Taiwan University Hospital Outline Overview Indication Stem cell source New revolution Cord

More information

AML:Transplant or ChemoTherapy?

AML:Transplant or ChemoTherapy? AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens

More information

Spontaneous recovery of ovarian function and fertility after cancer treatment

Spontaneous recovery of ovarian function and fertility after cancer treatment Rigshospitalet The Fertility Clinic Copenhagen, Denmark Spontaneous recovery of ovarian function and fertility after cancer treatment Kirsten Tryde Macklon, Ph.D. 5th society of reproductive medicine and

More information

Latest results of sibling HSCT in acquired AA. Jakob R Passweg

Latest results of sibling HSCT in acquired AA. Jakob R Passweg Latest results of sibling HSCT in acquired AA Jakob R Passweg Impact on Outcome: Patient Age, Disease Severity Title: Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and

More information

Article Stem cell transplantation for thalassaemia

Article Stem cell transplantation for thalassaemia RBMOnline - Vol 10. No 1. 2005 111-115 Reproductive BioMedicine Online; www.rbmonline.com/article/1525 on web 10 November 2004 Article Stem cell transplantation for thalassaemia Dr Javid Gaziev Javid Gaziev

More information

Lung Injury after HCT

Lung Injury after HCT Lung Injury after HCT J. Douglas Rizzo, MD, MS Financial Disclosure None SCS06_1.ppt Background HCT an important therapeutic modality for malignant and non-malignant diseases Pulmonary Toxicity common

More information

Stem Cell Transplantation

Stem Cell Transplantation Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor

More information

Chapter 11. Late Effects in Fanconi Anemia Patients Post-Transplant. Introduction. Overview

Chapter 11. Late Effects in Fanconi Anemia Patients Post-Transplant. Introduction. Overview Chapter 11 Late Effects in Fanconi Anemia Patients Post-Transplant Margaret L. MacMillan, MD, K. Scott Baker, MD, and John E. Wagner, MD Introduction A greater proportion of FA patients are now surviving

More information

Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate

Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute

More information

Where in the TED Does HCT Stuff Go?

Where in the TED Does HCT Stuff Go? Where in the TED Does HCT Stuff Go? Diane J. Knutson TED07_1.ppt Key Concepts What is an HSCT? Why perform one? Who can benefit? Mechanics of transplant Early and Late complications Where on new TED? TED07_2.ppt

More information

Donatore HLA identico di anni o MUD giovane?

Donatore HLA identico di anni o MUD giovane? Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events

More information

Reducing the burden of squamous cell carcinoma in Fanconi Anemia - Initial study questionnaire -

Reducing the burden of squamous cell carcinoma in Fanconi Anemia - Initial study questionnaire - Reducing the burden of squamous cell carcinoma in Fanconi Anemia - Initial study questionnaire - Today s Date (MM/DD/YYYY): / / Please note: If you do not want to answer a question, leave it blank. (Note

More information

Chapter 20: Clinical Management Checklist

Chapter 20: Clinical Management Checklist Chapter 20: Clinical Management Checklist Introduction Fanconi anemia (FA) is a complex disease that can affect all systems of the body. Patients are at risk for bone marrow failure, leukemia, squamous

More information

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant

Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant Factors that influence post transplantation fertility and ovarian function in women Total body irradiation (TBI) Drugs prescribed

More information

Aplastic Anemia Pathophysiology and Approach to Therapy

Aplastic Anemia Pathophysiology and Approach to Therapy Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes

More information

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant

More information

Late Effects After Autologous Bone Marrow Transplantation in Childhood

Late Effects After Autologous Bone Marrow Transplantation in Childhood Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1293 Late Effects After Autologous Bone Marrow Transplantation in Childhood BY PER FRISK ACTA UNIVERSITATIS UPSALIENSIS UPPSALA

More information

Disclosures. Investigator-initiated study funded by Astellas

Disclosures. Investigator-initiated study funded by Astellas Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development

More information

Stem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital

Stem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital Stem cell transplantation for haemoglobinopathies Dr P J Darbyshire Birmingham Childrens Hospital Survival by Cohort of Birth (N=977) 1.00 85-97 80-84 75-79 70-74 0.75 Survival Probability 0.50 0.25 P

More information

Need considerable resources material and human.

Need considerable resources material and human. TRAN VAN BINH INTRODUCTION Hematopoietic Stem cell transplantation: the best way to manage Malignancies and non Malignant blood disorders. Need considerable resources material and human. In developping

More information

Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin

Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin Published Ahead of Print on July 13, 2017, as doi:10.3324/haematol.2017.171215. Copyright 2017 Ferrata Storti Foundation. Long-term risk of cancer development in adult patients with idiopathic aplastic

More information

Gynecologic Considerations in Women with FA

Gynecologic Considerations in Women with FA Gynecologic Considerations in Women with FA RAHEL GHEBRE, M.D., MPH University of Minnesota Medical School Objectives Recommendation for Gynecologic Care FA girls starting at age 16 should establish a

More information

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891

More information

KEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus

KEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1

More information

Organ toxicity and quality of life after allogeneic bone marrow transplantation in pediatric patients: a single centre retrospective analysis

Organ toxicity and quality of life after allogeneic bone marrow transplantation in pediatric patients: a single centre retrospective analysis Bone Marrow Transplantation, (1999) 23, 1049 1053 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Organ toxicity and quality of life after allogeneic bone

More information

Stem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic

Stem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic Stem cell Survivorship: Searching for a solution to our success Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic Location of Centers Participating in t he CI BMTR 2 0 0 7................................................................................................................

More information

Anemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh

Anemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,

More information

Bone Marrow Transplantation and the Potential Role of Iomab-B

Bone Marrow Transplantation and the Potential Role of Iomab-B Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation

More information

Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions

Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions Susannah E. Koontz, PharmD, BCOP Clinical Pharmacy & Education Consultant Pediatric Hematology/Oncology and

More information

Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors

Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors Rainer F. Storb, Guido Lucarelli, Peter A. McSweeney, and Richard W. Childs Allogeneic hematopoietic cell transplantation

More information

Haemopoietic Stem Cell Transplantation

Haemopoietic Stem Cell Transplantation Haemopoietic Stem Cell Transplantation Current Status in Paediatric Disorders HSCT! Replacement of recipient HSC and derived lineages, by donor HSC! Unique organ transplant! Regenerative tissue! both recipient

More information